Literature DB >> 12894854

Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia.

Nobuhiko Uoshima1, Yuri Kamitsuji, Etsuko Maruya, Hiroh Saji.   

Abstract

A 31-year-old woman with advanced acute myeloid leukemia underwent non-T-cell-depleted (TCD) peripheral blood stem cell transplantation (PBSCT) with a reduced-intensity conditioning regimen. The donor was an HLA haploidentical 3-loci-mismatched complementary sibling who had not inherited maternal HLA antigens. Long-term fetomaternal microchimerism was detected by nested polymerase chain reaction with specific primer typing. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus with minidose methotrexate. Durable engraftment was achieved without severe acute GVHD, and complete remission was obtained. Thus non-TCD HLA haploidentical reduced-intensity PBSCT based on fetomaternal immunological tolerance appears to be feasible. Our results have important implications in the selection of alternative donors and conditioning regimens for allogeneic hematopoietic stem cell transplantation.

Entities:  

Mesh:

Year:  2003        PMID: 12894854     DOI: 10.1007/bf02983243

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  Tumour regression following stem cell infusion from daughter to microchimeric mother.

Authors:  K Tokita; P Terasaki; E Maruya; H Saji
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

2.  Microchimerism of maternal origin persists into adult life.

Authors:  S Maloney; A Smith; D E Furst; D Myerson; K Rupert; P C Evans; J L Nelson
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

3.  Successful non-T cell-depleted HLA haplo-identical three-loci mismatched hematopoietic stem cell transplantation from mother to son based on the feto-maternal microchimerism in chronic myelogenous leukemia.

Authors:  N Ochiai; C Shimazaki; S Fuchida; A Okano; T Sumikuma; E Ashihara; T Inaba; N Fujita; E Maruya; M Nakagawa
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

4.  Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts.

Authors:  S Tamaki; T Ichinohe; K Matsuo; N Hamajima; N Hirabayashi; H Dohy
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

5.  Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.

Authors:  M Sykes; F Preffer; S McAfee; S L Saidman; D Weymouth; D M Andrews; C Colby; R Sackstein; D H Sachs; T R Spitzer
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

6.  Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.

Authors:  Jon J van Rood; Fausto R Loberiza; Mei-Jie Zhang; Machteld Oudshoorn; Frans Claas; Mitchell S Cairo; Richard E Champlin; Robert Peter Gale; Olle Ringdén; Jill M Hows; Mary H Horowitz
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

7.  Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.

Authors:  R Martino; M D Caballero; J de la Serna; J L Díez-Martín; A Urbano-Ispízua; J F Tomás; J Odriozola; A León; C Canals; J San Miguel; J Sierra
Journal:  Bone Marrow Transplant       Date:  2002-07       Impact factor: 5.483

8.  Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. Molecular genetic evidence of the same clonal origin.

Authors:  T Nosaka; H Ohno; S Doi; S Fukuhara; H Miwa; K Kita; S Shirakawa; T Honjo; M Hatanaka
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

9.  Treatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2.

Authors:  L Shaffer; S Giralt; R Champlin; K W Chan
Journal:  Bone Marrow Transplant       Date:  1995-02       Impact factor: 5.483

10.  Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].

Authors:  H G Klingemann; A P Grigg; K Wilkie-Boyd; M J Barnett; A C Eaves; D E Reece; J D Shepherd; G L Phillips
Journal:  Blood       Date:  1991-12-15       Impact factor: 22.113

View more
  3 in total

1.  Philadelphia chromosome-positive acute lymphoblastic leukemia rescued with a second allogeneic stem cell transplantation from a haploidentical mother after relapse following cord blood transplantation.

Authors:  Tatsuyuki Kai; Hideo Kimura; Yutaka Shiga; Shin Mineishi; Satoshi Yoshihara; Hiroyasu Ogawa; Etsuko Maruya; Hiroh Saji; Hitoshi Ohto; Yukio Maruyama
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

2.  Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents.

Authors:  Hiromasa Yabe; Hiroyasu Inoue; Masae Matsumoto; Satoshi Hamanoue; Aiko Hiroi; Takashi Koike; Masahiro Sako; Mitsuhiro Fujiwara; Yasunori Ueda; Etsuko Maruya; Hiroh Saji; Shunichi Kato; Miharu Yabe
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

3.  Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents.

Authors:  Takao Yoshihara; Keiko Okada; Michihiro Kobayashi; Atsushi Kikuta; Koji Kato; Naoto Adachi; Akira Kikuchi; Hiroyuki Ishida; Yasuzou Hirota; Hiroshi Kuroda; Yoshihisa Nagatoshi; Takeshi Inukai; Kazutoshi Koike; Hisato Kigasawa; Hiroshi Yagasaki; Kiriko Tokuda; Tomoko Kishimoto; Takahide Nakano; Naoto Fujita; Hiroaki Goto; Yozo Nakazawa; Hirokazu Kanegane; Akinobu Matsuzaki; Yuko Osugi; Daiichiro Hasegawa; Nobuhiko Uoshima; Kazuhiro Nakamura; Masahiro Tsuchida; Ryuhei Tanaka; Arata Watanabe; Hiromasa Yabe
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.